Physician profile
Reinaldo E Rampolla
NPI 1386645356
$5,045.97
in general payments reported to CMS, 2019-2025
16 companies · $59.49 in 2025
The $59.49 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,632 · 2020: $288 · 2022: $380 · 2023: $353 · 2024: $1,333 · 2025: $59.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,254.78 | 2019 | |
| Paragonix Technologies, INC. | $877.68 | 2024 | Baroguard, Liverguard, Lungguard |
| La Jolla Pharmaceutical Company | $533.19 | 2019-2025 | Giapreza |
| Janssen Pharmaceuticals, INC | $270.03 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.76 | 2020 | |
| Inari Medical, INC. | $207.04 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $124.73 | 2019 | |
| Vapotherm INC | $123.93 | 2022 | |
| United Therapeutics Corporation | $102.60 | 2019-2022 | |
| Astellas Pharma Global Development | $79.01 | 2019 | |
| Zambon USA Ltd. | $73.31 | 2024 | |
| Boston Scientific Corporation | $49.80 | 2022 | |
| Ambu INC. | $46.88 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $24.69 | 2023 | Fasenra |
| Tetraphase Pharmaceuticals, INC. | $23.25 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $14.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reinaldo Rampolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.